MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study
Pediatrics International · 2026-01 · 68 (1)
DOI: 10.1111/ped.70476 ↗At a glance
Kohortenstudie in Pediatrics International, published online on 2026-07-13. Written by Min Ji Kim and 3 co-authors. Institution: Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea. Major MEDLINE topics: Mucocutaneous Lymph Node Syndrome, Immunoglobulins, Intravenous, COVID-19, Systemic Inflammatory Response Syndrome. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Fund of the Biomedical Research Institute, Jeonbuk National University Hospital.
Abstract (original language)
Background
Whether prior coronavirus disease 2019 (COVID‐19) independently influences treatment response in children with Kawasaki disease (KD) is unclear, as prior reports may have been confounded by overlap with multisystem inflammatory syndrome in children (MIS‐C). We investigated this in a nationwide cohort, accounting for these factors.
Methods
We conducted a retrospective cohort study using the Korean National Health Insurance Service database. Children diagnosed with KD on or after January 1, 2020 who received IVIG within 7 days were included. Prior COVID‐19 was defined as documented infection within 3 months before KD diagnosis. The primary outcome was second‐line treatment within 7 days after initial IVIG (composite of second IVIG or additional steroid). 1:1 propensity score matching was performed using age, sex, MIS‐C status, and steroid use with initial IVIG.
Results
Among 6572 eligible children, 512 had prior COVID‐19; 431 patients were matched per group. Second‐line treatment occurred in 32/431 (7.4%) versus 23/431 (5.3%) ( p = 0.265). Prior COVID‐19 was not independently associated with second‐line treatment (adjusted HR 1.42; 95% CI 0.83–2.43). In subgroup analysis, elevated risk was confined to children with concurrent MIS‐C (HR 3.01; 95% CI 1.34–6.74); prior COVID‐19 without MIS‐C showed no increase (HR 1.18; 95% CI 0.66–2.11). Sensitivity analyses excluding MIS‐C and restricted to 2022 onward were consistent.
Conclusions
Prior COVID‐19 alone was not independently associated with second‐line treatment once MIS‐C overlap and concurrent steroid use were accounted for. The elevated treatment escalation rate appeared driven primarily by MIS‐C, highlighting the importance of distinguishing MIS‐C from classic KD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Hospital, Jeonju, Korea.
- Department of Preventive Medicine, College of Medicine, Jeonbuk National University, Jeonju, Korea.
- Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Korea.
- Department of Pediatrics, Jeonbuk National University Children's Hospital, Jeonju, Korea.
ORCID profiles: Min Ji Kim, Jong Seung Kim, Jee Young Hong, Jihye You
Funding
- the Fund of the Biomedical Research Institute, Jeonbuk National University Hospital
Cite
APA
Kim, M. J., Kim, J. S., Hong, J. Y., & You, J. (2026). MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70476
Vancouver
Kim MJ, Kim JS, Hong JY, You J. MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study. Pediatrics International. 2026;68(1). doi:10.1111/ped.70476
BibTeX
@article{Kim2026,
author = {Kim, Min Ji and Kim, Jong Seung and Hong, Jee Young and You, Jihye},
title = {MIS ‐C Overlap, Not Prior COVID ‐19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study},
journal = {Pediatrics International},
year = {2026},
volume = {68},
number = {1},
doi = {10.1111/ped.70476}
}
EUVIMED